This Plain Language Summary of publication article (PLSP) from Future Endocrinology & Metabolism, discusses a clinical study evaluating the effectiveness and safety of abaloparatide (Tymlos®), an injectable osteoporosis medication, in men with osteoporosis. The study compared abaloparatide to a placebo and led to its FDA approval for increasing bone density in men at high risk of fractures, expanding its previous approval for postmenopausal women.

Visit the site using this link to read the article.

This PLSP is based on an article called “The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial” and was published in JBMR.

Visit Oxford Academic using the link to read the original article.